While confirmation of this finding is pending the results of the PALOMA-2/TRIO-22 study which is a randomized, double-blind study of palbociclib and letrozole versus placebo and letrozole, results from the double-blind, placebo-controlled PALOMA-3 study, evaluating palbociclib and fulvestrant versus fulvestrant in a hormone-refractory population confirm the important role of CDK 4/6 inhibition in ER+/HER2– breast cancer. The gene discussed is ERBB2; the disease is breast cancer.